Lytix Biopharma will together with PI Dr James Spicer present a poster with preliminary data from a phase I/II study with LTX-315 at the ASCO Annual Meeting 2018 in Chicago, IL.
The Annual Meeting brings together more than 32,000 oncology professionals from around the world to discuss state-of-the-art treatment modalities, new therapies, and ongoing controversies in the field.
The title of the poster is “A phase I/II study of the oncolytic peptide LTX-315 combined with checkpoint inhibition generates de novo T-cell responses and clinical benefit in patients with advanced solid tumors”, and it will be presented at the session ‘Developmental Therapeutics —Immunotherapy ‘, June 4th, 2018, 8:00 AM-11:30 AM.
Read short article about Lytix at ASCO
Photo added after poster session:
